Literature DB >> 10540230

Cell surface expression and metabolism of major histocompatibility complex class II invariant chain (CD74) by diverse cell lines.

G L Ong1, D M Goldenberg, H J Hansen, M J Mattes.   

Abstract

We previously described the processing of antibodies to CD74 (the major histocompatibility complex class II-associated invariant chain, Ii), by B-cell lymphoma cell lines. These cells expressed relatively low levels of Ii on the surface, but the molecules were rapidly internalized and replaced by new molecules, so that approximately 8 x 10(6) antibody molecules per cell were taken up per day. We herein report the results of similar studies with other cell types, namely a melanoma, a colon carcinoma, a T-cell lymphoma and B-lymphoblastoid cell lines. The melanoma and the carcinoma were treated with interferon-gamma to induce high levels of the antigen. The T-cell lymphoma, HUT 78, was selected specifically because it was previously reported to lack cell surface Ii, while expressing the molecule intracellularly. However, HUT 78 displayed Ii on the cell surface, as did the other cell lines tested, and catabolism of the antibody was very fast on all of the cell lines. The capacity of four of the cell lines for cumulative antibody uptake was evaluated, using 'residualizing' radiolabels, which are trapped within the cell after catabolism of the antibody to which they were conjugated. A high level of uptake was observed in all cases, although there was significant variation between the cell lines. With melanoma SK-MEL-37, the total LL1 uptake in 24 hr was nearly 10(7) molecules per cell and the average turnover time for Ii on the cell surface was 4 min; with carcinoma HT-29, the total LL1 uptake in 24 hr was approximately 10(6) molecules per cell, and the average turnover time for Ii on the cell surface was 27 min. Based on the cell content of mature class II antigens (alphabeta), these data suggest that a large fraction, or all, of immature class II molecules (alphabetaIi) reach the cell surface before entering the peptide-loading compartment, independent of the particular cell type.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10540230      PMCID: PMC2326920          DOI: 10.1046/j.1365-2567.1999.00868.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  28 in total

1.  Human major histocompatibility complex class II invariant chain is expressed on the cell surface.

Authors:  C J Wraight; P van Endert; P Möller; J Lipp; N R Ling; I C MacLennan; N Koch; G Moldenhauer
Journal:  J Biol Chem       Date:  1990-04-05       Impact factor: 5.157

2.  Intracellular catabolism of radiolabeled anti-CD3 antibodies by leukemic T cells.

Authors:  F Geissler; S K Anderson; O Press
Journal:  Cell Immunol       Date:  1991-10-01       Impact factor: 4.868

3.  Cell surface expression of invariant gamma-chain of class II histocompatibility antigens in human skin.

Authors:  L Claesson-Welsh; A Scheynius; U Tjernlund; P A Peterson
Journal:  J Immunol       Date:  1986-01       Impact factor: 5.422

4.  Lack of detectable endocytosis of B lymphocyte MHC class II antigens using an antibody-independent technique.

Authors:  J E Davis; P Cresswell
Journal:  J Immunol       Date:  1990-02-01       Impact factor: 5.422

5.  Intracellular pathway for the generation of functional MHC class II peptide complexes in immature human dendritic cells.

Authors:  C Saudrais; D Spehner; H de la Salle; A Bohbot; J P Cazenave; B Goud; D Hanau; J Salamero
Journal:  J Immunol       Date:  1998-03-15       Impact factor: 5.422

6.  Differential expression of Ia and Ia-associated invariant chain in mouse tissues after in vivo treatment with IFN-gamma.

Authors:  F Momburg; N Koch; P Möller; G Moldenhauer; G W Butcher; G J Hämmerling
Journal:  J Immunol       Date:  1986-02-01       Impact factor: 5.422

7.  Two new monoclonal antibodies, EPB-1 and EPB-2, reactive with human lymphoma.

Authors:  E J Pawlak-Byczkowska; H J Hansen; A S Dion; D M Goldenberg
Journal:  Cancer Res       Date:  1989-08-15       Impact factor: 12.701

8.  Expression of Ia-like antigens on cultured human malignant melanoma cell lines.

Authors:  R J Winchester; C Y Wang; A Gibofsky; H G Kunkel; K O Lloyd; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1978-12       Impact factor: 11.205

9.  Induction of various HLA class II molecules in a human colonic adenocarcinoma cell line.

Authors:  L M Sollid; G Gaudernack; G Markussen; D Kvale; P Brandtzaeg; E Thorsby
Journal:  Scand J Immunol       Date:  1987-02       Impact factor: 3.487

10.  Surface antigens of melanoma and melanocytes. Specificity of induction of Ia antigens by human gamma-interferon.

Authors:  A N Houghton; T M Thomson; D Gross; H F Oettgen; L J Old
Journal:  J Exp Med       Date:  1984-07-01       Impact factor: 14.307

View more
  22 in total

1.  Phase I study of the anti-CD74 monoclonal antibody milatuzumab (hLL1) in patients with previously treated B-cell lymphomas.

Authors:  Peter Martin; Richard R Furman; Sarah Rutherford; Jia Ruan; Scott Ely; June Greenberg; Morton Coleman; Stanley J Goldsmith; John P Leonard
Journal:  Leuk Lymphoma       Date:  2015-05-12

2.  CD74 and macrophage migration inhibitory factor as therapeutic targets in gastric cancer.

Authors:  Ying-Xia Zheng; Ming Yang; Ting-Ting Rong; Xiang-Liang Yuan; Yan-Hui Ma; Zhi-Hao Wang; Li-Song Shen; Long Cui
Journal:  World J Gastroenterol       Date:  2012-05-14       Impact factor: 5.742

3.  CD74 is a survival receptor on colon epithelial cells.

Authors:  Nitsan Maharshak; Sivan Cohen; Frida Lantner; Gili Hart; Lin Leng; Richard Bucala; Idit Shachar
Journal:  World J Gastroenterol       Date:  2010-07-14       Impact factor: 5.742

4.  Enhanced expression of CD74 in gastrointestinal cancers and benign tissues.

Authors:  David V Gold; Rhona Stein; Jack Burton; David M Goldenberg
Journal:  Int J Clin Exp Pathol       Date:  2010-11-23

5.  Helicobacter pylori binds to CD74 on gastric epithelial cells and stimulates interleukin-8 production.

Authors:  Ellen J Beswick; David A Bland; Giovanni Suarez; Carlos A Barrera; Xuejung Fan; Victor E Reyes
Journal:  Infect Immun       Date:  2005-05       Impact factor: 3.441

6.  Measurement of ex vivo resistance to proteasome inhibitors, IMiDs, and daratumumab during multiple myeloma progression.

Authors:  Zachary J Walker; Michael J VanWyngarden; Brett M Stevens; Diana Abbott; Andrew Hammes; Christophe Langouët-Astrie; Clayton A Smith; Brent E Palmer; Peter A Forsberg; Tomer M Mark; Craig T Jordan; Daniel W Sherbenou
Journal:  Blood Adv       Date:  2020-04-28

Review 7.  The development of potential antibody-based therapies for myeloma.

Authors:  Daniel W Sherbenou; Christopher R Behrens; Yang Su; Jeffrey L Wolf; Thomas G Martin; Bin Liu
Journal:  Blood Rev       Date:  2014-09-28       Impact factor: 8.250

8.  The Helicobacter pylori urease B subunit binds to CD74 on gastric epithelial cells and induces NF-kappaB activation and interleukin-8 production.

Authors:  Ellen J Beswick; Irina V Pinchuk; Kyle Minch; Giovanni Suarez; Johanna C Sierra; Yoshio Yamaoka; Victor E Reyes
Journal:  Infect Immun       Date:  2006-02       Impact factor: 3.441

9.  T Cells Regulate Peripheral Naive Mature B Cell Survival by Cell-Cell Contact Mediated through SLAMF6 and SAP.

Authors:  Lihi Radomir; Sivan Cohen; Matthias P Kramer; Eszter Bakos; Hadas Lewinsky; Avital Barak; Ziv Porat; Richard Bucala; Polina Stepensky; Shirly Becker-Herman; Idit Shachar
Journal:  J Immunol       Date:  2017-09-13       Impact factor: 5.422

10.  Bioinformatics analysis of gene expression alterations conferring drug resistance in tumor samples from melanoma patients with EGFR-activating BRAF mutations.

Authors:  Yang Yu; Xueer Wang; Qinglin Li; Min Zhang; Pengcheng Xu; Yinghua Chen; Yuan Yan; Lin Zhang
Journal:  Oncol Lett       Date:  2017-11-02       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.